Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr:139:156473.
doi: 10.1016/j.phymed.2025.156473. Epub 2025 Feb 12.

Baicalin alleviates lipid metabolism disorders in diabetic kidney disease via targeting FKBP51

Mi Li  1 , Hong-Yan Zhu  1 , Shu-Yan Zhao  1 , Xian-Deng Li  1 , Shuang-Mei Tong  1 , Jing Ma  1 , A-Jing Xu  2 , Jian Zhang  3
Affiliations

Baicalin alleviates lipid metabolism disorders in diabetic kidney disease via targeting FKBP51

Mi Li et al. Phytomedicine. 2025 Apr.

Abstract

Background: Diabetic kidney disease (DKD) represents the primary aetiological factor in end-stage renal disease, wherein lipid metabolism disorders contribute to the progression of DKD. Baicalin, a composition from Scutellaria baicalensis, has exhibited the potential to mitigate lipid metabolism disorders of DKD, but the precise mechanisms remain unclear.

Methods: High-fat-diet (HFD)/streptozotocin (STZ)-induced DKD mouse model was established to appraise the effects of baicalin on renal function, dyslipidemia, and renal ectopic lipid deposition. The effects of baicalin on lipid accumulation in vitro were assessed in tubular epithelial cells derived from mice (TCMK-1) treated with palmitic acid (PA). The potential targets of baicalin were identified by drug affinity responsive target stability (DARTS) -LC/MS. The impact of the identified target on lipid metabolism was elucidated in TCMK-1 cells through both knockdown and overexpression experiments.

Results: The findings indicated that baicalin effectively mitigated dyslipidemia and renal ectopic lipid deposition in the HFD/STZ-induced DKD mouse model. FK506-binding protein 51(FKBP51) was identified as an endogenous target of baicalin, with the Tyr113 residue playing a crucial role in the binding interaction. Additionally, FKBP51 knockdown brought about intracellular lipid accumulation, but FKBP51 overexpression was found to effectively counteract the lipid accumulation induced by PA. Further investigation revealed that FKBP51 regulates lipid accumulation through the Tyr113 residue. Notably, the lipid-lowering effect of baicalin was diminished following FKBP51 knockdown.

Conclusion: This study first identifies that FKBP51 is beneficial for lipid metabolism homeostasis in DKD and suggests baicalin as an effective molecule for targeting FKBP51 in the treatment of lipid metabolism disorders associated with DKD.

Keywords: Baicalin; Diabetic kidney disease; FKBP51; Lipid metabolism disorders.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

LinkOut - more resources